Post Content

Previous articlePα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
Next articleWeekly Psychedelic Policy Briefing: October 12, 2026